Regulatory
FDA Approves Besremi for Essential Thrombocythemia — the First New Treatment in Nearly 30 Years
The long-acting interferon, already used for a related blood cancer, beat an older drug at controlling platelet counts and cutting clot-related events in a Phase 3 trial.